A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Latest Information Update: 31 Jan 2020
At a glance
- Drugs Cetuximab (Primary) ; Antineoplastics
- Indications Head and neck cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Alkem Laboratories; Enzene Biosciences
- 31 Jan 2020 New trial record